Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol.

ABSTRACT:

Introduction

Regorafenib was recently approved for patients with pretreated advanced colorectal cancer (aCRC), despite a moderate improvement of the patients' outcome, and significant toxicities. Based on previous studies showing that early fluorodeoxyglucose-positron emission tomography (FDG-PET)-based metabolic response assessment (MRA) might adequately select patients unlikely to benefit from treatment, the RegARd-C trial uses early MRA to identify likely non-responders to regorafenib in a population of patients with aCRC and guide a comprehensive evaluation of genomic and epigenetic determinants of resistance to treatment.

Methods and analysis

RegARd-C is a multicentric prospective study. Its primary objective is to identify non-benefitters from regorafenib given at 160 

SUBMITTER: Hendlisz A 

PROVIDER: S-EPMC4360786 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature